Page 83 - GTM-2-2

Global Translational Medicine Nanoparticles in cancer treatment

Funding 7. Chen Y, Gao DY, Huang L, 2015, In vivo delivery of miRNAs
for cancer therapy: Challenges and strategies. Adv Drug
None. Deliv Rev, 81: 128–141.
Conflict of interest https://doi.org/10.1016/j.addr.2014.05.009

The author declared no competing interest. 8. Zhang F, Correia A, Mäkilä E, et al., 2017, Receptor-
mediated surface charge inversion platform based on porous
Author contributions silicon nanoparticles for efficient cancer cell recognition
and combination therapy. ACS Appl Mater Interfaces,
Conceptualization: All authors 9: 10034–10046.
Writing – original draft: All authors https://doi.org/10.1021/acsami.7b02196
Writing – review & drafting: All authors
9. Bahrami B, Hojjat-Farsangi M, Mohammadi H, et al., 2017,
Ethics approval and consent to participate Nanoparticles and targeted drug delivery in cancer therapy.
Immunol Lett, 190: 64–83.
Not applicable.
https://doi.org/10.1016/j.imlet.2017.07.015
Consent for publication 10. Yao Y, Zhou Y, Liu L, et al., 2020, Nanoparticle-based drug
delivery in cancer therapy and its role in overcoming drug
Not applicable.
resistance. Front Mol Biosci, 7: 193.
Availability of data https://doi.org/10.3389/fmolb.2020.00193
Not applicable. 11. Decuzzi P, Pasqualini R, Arap W, et al., 2009, Intravascular
delivery of particulate systems: Does geometry really matter?
References Pharm Res, 26: 235–243.
1. Gavas S, Quazi S, Karpiński TM, 2021, Nanoparticles for https://doi.org/10.1007/s11095-008-9697-x
cancer therapy: Current progress and challenges. Nanoscale 12. Venturoli D, Rippe B, 2005, Ficoll and dextran vs. globular
Res Lett, 16: 173. proteins as probes for testing glomerular permselectivity:
https://doi.org/10.1186/s11671-021-03628-6 Effects of molecular size, shape, charge, and deformability.
Am J Phys Renal Physiol, 288: F605–F613.
2. Boisseau P, Loubaton B, 2011, Nanomedicine,
nanotechnology in medicine. C R Phys, 12: 620–636. https://doi.org/10.1152/ajprenal.00171.2004
https://doi.org/10.1016/j.crhy.2011.06.001 13. Prokop A, Davidson JM, 2008, Nanovehicular intracellular
delivery systems. J Pharm Sci, 97: 3518–3590.
3. Bertrand N, Wu J, Xu X, et al., 2014, Cancer nanotechnology:
The impact of passive and active targeting in the era of https://doi.org/10.1002/jps.21270
modern cancer biology. Adv Drug Deliv Rev, 66: 2–25. 14. Yang Q, Jones SW, Parker CL, et al., 2014, Evading
https://doi.org/10.1016/j.addr.2013.11.009 immune cell uptake and clearance requires PEG grafting at
densities substantially exceeding the minimum for brush
4. Kalyane D, Raval N, Maheshwari R, et al., 2019, conformation. Mol Pharm, 11: 1250–1258.
Employment of enhanced permeability and retention effect
(EPR): Nanoparticle-based precision tools for targeting of https://doi.org/10.1021/mp400703d
therapeutic and diagnostic agent in cancer. Mater Sci Eng C 15. Perrault SD, Walkey C, Jennings T, et al., 2009, Mediating
Mater Biol Appl, 98: 1252–1276. tumor targeting efficiency of nanoparticles through design.
https://doi.org/10.1016/j.msec.2019.01.066 Nano Lett, 9: 1909–1915.
5. O’Brien MER, Wigler N, Inbar M, et al., 2004, Reduced https://doi.org/10.1021/nl900031y
cardiotoxicity and comparable efficacy in a phase III trial 16. Anselmo AC, Zhang M, Kumar S, et al., 2015, Elasticity
of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) of nanoparticles influences their blood circulation,
versus conventional doxorubicin for first-line treatment of phagocytosis, endocytosis, and targeting. ACS Nano,
metastatic breast cancer. Ann Oncol, 15: 440–449. 9: 3169–3177.
https://doi.org/10.1093/annonc/mdh097 https://doi.org/10.1021/acsnano.5b00147
6. Saha RN, Vasanthakumar S, Bende G, et al., 2010, 17. Zylberberg C, Matosevic S, 2016, Pharmaceutical liposomal
Nanoparticulate drug delivery systems for cancer drug delivery: A review of new delivery systems and a look
chemotherapy. Mol Membr Biol, 27: 215–231. at the regulatory landscape. Drug Deliv, 23: 3319–3329.
https://doi.org/10.3109/09687688.2010.510804 https://doi.org/10.1080/10717544.2016.1177136

Volume 2 Issue 2 (2023) 4 https://doi.org/10.36922/gtm.0394